



Η αξία της εκλεκτικής αναστολής της IL-23 στην ψωριασική αρθρίτιδα

Κυριακή Μποκή
Ρευματολογική Μονάδα
Σισμανόγλειο Νοσοκομείο

Melinda, *Tree of Life*

Χαλκιδική 4-9-2021

Σύγκρουση συμφερόντων
Disclosures-Conflict of interest

Παρούσα παρουσίαση: *JANSSEN*



Εκπαιδευτικές-ερευνητικές-συμβουλευτικές επιχορηγήσεις την τελευταία διετία:
Abbvie, Boehringer Ingelheim, Genesis, Gilead, Lilly, UCB

Το φάσμα των Σπονδυλαρθρίτιδων ΣΠΑ




Σπονδυλαρθρίτιδες


Κοινά κλινικά χαρακτηριστικά




Από την παθολογία στη θεραπεία




IL-23: κύριος ρυθμιστής



Παθοφυσιολογία: Ψωρίασης / Ψωριασικής Αρθρίτιδας



IL-23 και T κύτταρα των ενθέσεων προάγουν ενθεσίτιδα και οστεοπαραγωγή στη σπονδυλαρθρίτιδα



↑ IL-23 έκφραση, ενεργοποιεί τοπικά T κύτταρα ενθέσεων ⇒ φλεγμονή (ενθεσίτιδα) & παραγωγή νέου οστού (μέσω IL-17, IL-22 ...)


UPR, unfolded protein response.

Lories RJ et al. Nat Med 2012;18:1018-9 (with permission)




Οι Σπονδυλαρθροπάθειες χαρακτηρίζονται από
φλεγμονή σε σημεία που δέχονται stress


Ψωριασική ονυχία




Transitioning From PsO to PsA



Από την ψωρίαση στη ψωριασική αρθρίτιδα




DMARDs Approved for PsA in the Last 20 Years



GRAPPA 2021 Treatment Recommendations for PsA

Consider which domains are involved, patient preference, previous/concomitant therapies; choice of therapy should address as many domains as possible



Comorbidities and associated conditions may impact choice of therapy and/or guide monitoring


Treat, periodically re-evaluate treatment goals and modify therapy as required

→ Standard Therapeutic Route - - - - - Expedited Therapeutic Route

Adapted from Coates et al. EULAR 2021 #OP0229 [oral presentation].

Guselkumab mechanism of action¹⁻³

- 1 Guselkumab competitively binds to the p19 subunit of IL-23
- 2 This binding inhibits the IL-23 cytokine from binding to the IL-23 receptor
- 3 This inhibition subsequently prevents the intracellular and downstream signaling of IL-23
- 4 The IL-12 signaling pathway is maintained



Phase 3 Clinical Development of Guselkumab in PsA

Trial	Phase	Study Population	
DISCOVER-1	Phase 3, bio-naïve and bio-experienced study (DISCOVER-1) ^{2,3}	Patients are Bio-naive or Bio-experienced. Bio-experienced patients received ≤2 prior anti-TNFα agents, accounting for approximately 30% of the overall study population* .	<p>70% patients = Naïve to bDMARDs</p> <p>30% = TNF experienced</p>
DISCOVER-2	Phase 3, bio-naïve study (DISCOVER-2) ^{4,5}	All patients are bio-naïve and have had an inadequate response to standard therapies (e.g. DMARDs, apremilast and NSAIDs)	<p>100% patients = Naïve to bDMARDs</p>
COSMOS	Phase 3, bio experienced study	All patients are Bio-experienced. Bio-experienced patients received previous treatment with either 1 or 2 anti-TNF alpha agents.	<p>100% patients = TNF experienced</p>